A trial to determine the tolerance and immunogenicity of a recombinant canarypox vaccine (vCP1452) and two mixtures of lipopeptides (LIPO-5 and LIPO-6T) alone or in association, in HIV-negative, healthy adult volunteers

Trial Details:

I Completed
French National Agency for Research on AIDS and viral hepatitis (ANRS) March 01, 1999
ALVAC vCP1452,LIPO-5,LIPO-6T Canarypox env, gag and pol genes and CTL epitopes nef and pol B; 6 lipopeptides containing CTL epitopes from the Env, Gag and Nef B; Gag, Nef, and Pol B, and one lipopeptide derived from tetanus toxoid
ALVAC vCP1452 Viral Vector - Pox
LIPO-6T Protein
LIPO-5 Protein
France 60